KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Capital Expenditures (2019 - 2025)

Royalty Pharma's Capital Expenditures history spans 6 years, with the latest figure at $733.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 47.8% year-over-year to $733.7 million; the TTM value through Dec 2025 reached $2.4 billion, down 3.19%, while the annual FY2025 figure was $1.7 billion, 32.25% down from the prior year.
  • Capital Expenditures for Q4 2025 was $733.7 million at Royalty Pharma, up from $1.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.3 billion in Q3 2021 and bottomed at $85000.0 in Q1 2022.
  • The 5-year median for Capital Expenditures is $373.3 million (2022), against an average of $489.7 million.
  • The largest annual shift saw Capital Expenditures tumbled 99.98% in 2022 before it soared 707788.24% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $171.7 million in 2021, then surged by 45.71% to $250.2 million in 2022, then tumbled by 75.84% to $60.4 million in 2023, then skyrocketed by 721.26% to $496.4 million in 2024, then surged by 47.8% to $733.7 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Capital Expenditures are $733.7 million (Q4 2025), $1.1 million (Q1 2025), and $496.4 million (Q4 2024).